- Home
- ZVRA vs ERAS Comparison
ZVRA vs ERAS Comparison
Compare ZVRA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- ERAS
- Stock Information
- Founded
- ZVRA 2006
- ERAS 2018
- Country
- ZVRA United States
- ERAS United States
- Employees
- ZVRA N/A
- ERAS N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ZVRA Health Care
- ERAS Health Care
- Exchange
- ZVRA Nasdaq
- ERAS Nasdaq
- Market Cap
- ZVRA 467.6M
- ERAS 439.7M
- IPO Year
- ZVRA 2015
- ERAS 2021
- Fundamental
- Price
- ZVRA $8.99
- ERAS $2.66
- Analyst Decision
- ZVRA Strong Buy
- ERAS Strong Buy
- Analyst Count
- ZVRA 7
- ERAS 7
- Target Price
- ZVRA $21.71
- ERAS $3.86
- AVG Volume (30 Days)
- ZVRA 1.5M
- ERAS 1.2M
- Earning Date
- ZVRA 11-05-2025
- ERAS 11-12-2025
- Dividend Yield
- ZVRA N/A
- ERAS N/A
- EPS Growth
- ZVRA N/A
- ERAS N/A
- EPS
- ZVRA 0.54
- ERAS N/A
- Revenue
- ZVRA $84,388,000.00
- ERAS N/A
- Revenue This Year
- ZVRA $336.43
- ERAS N/A
- Revenue Next Year
- ZVRA $54.26
- ERAS N/A
- P/E Ratio
- ZVRA $16.52
- ERAS N/A
- Revenue Growth
- ZVRA 244.60
- ERAS N/A
- 52 Week Low
- ZVRA $6.19
- ERAS $1.01
- 52 Week High
- ZVRA $13.16
- ERAS $3.30
- Technical
- Relative Strength Index (RSI)
- ZVRA 38.60
- ERAS 61.27
- Support Level
- ZVRA $8.51
- ERAS $2.21
- Resistance Level
- ZVRA $9.69
- ERAS $2.41
- Average True Range (ATR)
- ZVRA 0.58
- ERAS 0.18
- MACD
- ZVRA -0.15
- ERAS 0.01
- Stochastic Oscillator
- ZVRA 15.26
- ERAS 78.23
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.